Structure of Fostamatinib
CAS No.: 901119-35-5
*Storage:
*Shipping:
Fostamatinib (R788) is the oral prodrug of R406. R406 is a potent, orally active, ATP-competitive inhibitor of Syk/FLT3 with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50 = 63 nM) and Lck (IC50 = 37 nM).
Synonyms: R788
4.5
*For Research Use Only !
Change View
Size | Price | US Stock | Global Stock | In Stock |
1mg | łËď¶ÊÊ | Inquiry | Inquiry | |
2mg | ł§î¶ÊÊ | Inquiry | Inquiry | |
5mg | łÿò¶ÊÊ | Inquiry | Inquiry | |
10mg | łó˶ÊÊ | Inquiry | Inquiry | |
25mg | łÇ§î¶ÊÊ | Inquiry | Inquiry | |
50mg | łË§Í¶ÊÊ | Inquiry | Inquiry | |
100mg | ł§îò¶ÊÊ | Inquiry | Inquiry | |
250mg | łòÇͶÊÊ | Inquiry | Inquiry |
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
łËď¶ÊÊ
ł§î¶ÊÊ
łÿò¶ÊÊ
łó˶ÊÊ
łÇ§î¶ÊÊ
łË§Í¶ÊÊ
ł§îò¶ÊÊ
łòÇͶÊÊ
In Stock
- +
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 901119-35-5 |
Formula : | C23H26FN6O9P |
M.W : | 580.46 |
SMILES Code : | O=P(O)(OCN1C2=NC(NC3=NC(NC4=CC(OC)=C(OC)C(OC)=C4)=NC=C3F)=CC=C2OC(C)(C)C1=O)O |
Synonyms : |
R788
|
MDL No. : | MFCD16628163 |
GHS Pictogram: | ![]() |
Signal Word: | Warning |
Hazard Statements: | H302 |
Precautionary Statements: | P280-P305+P351+P338 |
Target |
|
In Vitro:
Cell Line
| Concentration | Treated Time | Description | References |
Kidney tubular epithelial cell line (P cells) | 200 nM | 48 h | To evaluate the effect of R406 (active metabolite of Fostamatinib) on MUC1 protein levels; results showed R406 significantly reduced MUC1 abundance on the plasma membrane and increased its intracellular distribution | PMC7691435 |
MWCL.1 cells | 1 μM | 3 days | To evaluate the effect of Fostamatinib on the viability of MWCL-1 cells, results showed that 1 μM Fostamatinib significantly reduced cell viability after 3 days, inducing cell cycle arrest and apoptosis. | PMC4737551 |
BCWM.1 cells | 1 μM | 3 days | To evaluate the effect of Fostamatinib on the viability of BCWM.1 cells, results showed that 1 μM Fostamatinib significantly reduced cell viability after 3 days, inducing cell cycle arrest and apoptosis. | PMC4737551 |
EBV+ B-cell lymphoma PTLD lines | 0-10 μM | 96 h | Induces apoptosis and cell cycle arrest while decreasing downstream PI3K/Akt signaling | PMC4008139 |
Bone marrow monocytes | 10 ng/ml GM-CSF and 10 ng/ml IL-3 | 5 days | To evaluate the effect of Fostamatinib on GM-CSF/IL-3 stimulated bone marrow monocyte colony formation, results showed that Fostamatinib reduced GM-CSF/IL-3 stimulated bone marrow monocyte colony formation. | PMC4759214 |
Ly6Chigh monocytes | 30 ng/ml M-CSF | 16 h | To evaluate the effect of Fostamatinib on monocyte to macrophage differentiation, results showed that Fostamatinib blocked M-CSF stimulated monocyte to macrophage differentiation. | PMC4759214 |
In Vivo:
Species
| Animal Model
| Administration | Dosage | Frequency | Description | References |
C57BL/6J mice | Ischemia/reperfusion (I/R)-induced acute lung injury model | Oral | 3 g/kg | Once daily for 10 days | To evaluate the effect of R788 on MUC1 levels in vivo; results showed R788 significantly reduced MUC1 abundance in lung epithelial cells | PMC7691435 |
Mice | Silicosis mouse model | Oral gavage | 80 mg/kg | Once daily for two weeks | To investigate the effect of Fostamatinib on p-SYK levels and pulmonary fibrosis in a silicosis mouse model. Results showed that Fostamatinib significantly inhibited p-SYK levels and effectively alleviated silica-induced alveolitis and pulmonary fibrosis. | PMC9098425 |
Non-obese diabetic mice | MWCL-1 cell xenograft model | Intraperitoneal injection | 80 mg/kg | Three times a week for 45 days | To evaluate the anti-tumor activity of Fostamatinib in the MWCL-1 cell xenograft model, results showed that Fostamatinib significantly slowed tumor growth. | PMC4737551 |
Mice | Apoe-/- mice on high cholesterol diet | Oral | 0.3% (w/w) | Continued for 8 weeks | To evaluate the effect of Fostamatinib on high cholesterol diet-induced atherosclerosis, results showed that Fostamatinib reduced the formation of atherosclerotic plaques and decreased the number of Ly6Chigh monocytes and macrophages. | PMC4759214 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT05613296 | ITP - Immune Thrombocytopenia|... More >>Chronic ITP|Refractory ITP Less << | UNKNOWN | 2025-12-23 | - | |
NCT05904093 | Sickle Cell Disease|Hb-SS Dise... More >>ase|Hemoglobin S|Disease Sickle Cell Anemia|Sickle Cell Disorders|Hemoglobin Beta Thalassemia Disease Less << | PHASE1 | RECRUITING | 2026-05-14 | National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less << |
NCT01499303 | Diffuse Large B-Cell Lymphoma | PHASE2 | COMPLETED | 2025-10-13 | Research Site, Huntsville, Ala... More >>bama, United States|Research Site, Denver, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Sarasota, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Iowa City, Iowa, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Hackensack, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Columbus, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, London, United Kingdom|Research Site, Southampton, United Kingdom Less << |
NCT05040698 | Hidradenitis Suppurativa | PHASE2 | COMPLETED | 2023-01-27 | Holdsworth House Medical Pract... More >>ice, Sydney, New South Wales, 2010, Australia Less << |
NCT05030675 | Refractory Chronic Myelomonocy... More >>tic Leukemia|Refractory Myelodysplastic Syndrome Less << | PHASE1 | COMPLETED | 2024-08-08 | M D Anderson Cancer Center, Ho... More >>uston, Texas, 77030, United States Less << |
NCT03991780 | Renal Transplant Rejection | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | 2025-10-15 | Imperial College NHS Healthcar... More >>e Trust, London, W12 0HS, United Kingdom Less << |
NCT04904276 | ITP|Immune Thrombocytopenia | TERMINATED | 2022-11-17 | Advanced Research, Tamarac, Fl... More >>orida, 33321, United States|Simmons Cancer Institute at Southern Illinois University, Springfield, Illinois, 62702, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Saint Agnes Hospital, Baltimore, Maryland, 21229, United States|The Center for Cancer and Blood Disorders, Bethesda, Maryland, 20817, United States|Maryland Oncology Hematology, P.A, Clinton, Maryland, 20735, United States|Maryland Oncology Hematology, P.A, Columbia, Maryland, 21044, United States|Maryland Oncology Hematology, P.A, Rockville, Maryland, 20850, United States|Maryland Oncology Hematology, P.A, Silver Spring, Maryland, 20904, United States|Boston Medical Center, Boston, Massachusetts, 02118, United States|Washington University, Saint Louis, Missouri, 63130, United States|Regional Cancer Care Associates, LLC, Little Silver, New Jersey, 07739, United States|New York Medical College Westchester Medical Center, Valhalla, New York, 10532, United States|New York Medical College, Valhalla, New York, 10595, United States Less << | |
NCT06071520 | Primary Immune Thrombocytopeni... More >>a Less << | COMPLETED | 2023-06-30 | Hospital Puerta del Mar, Cadiz... More >>, Cádiz, 11009, Spain|Hospital Universitario de Jerez de la Frontera, Jerez De La Frontera, Cádiz, 11407, Spain|Hospital de Puerto Real, Puerto Real, Cádiz, 11510, Spain|Hospital de Riotinto, Minas de Riotinto, Huelva, 21660, Spain|Hospital de la Serranía de Ronda, Ronda, Málaga, 29400, Spain|Hospital de la Merced de Osuna, Osuna, Sevilla, 41640, Spain|Hospital Universitario Virgen de las Nieves, Granada, 18014, Spain|Hospital Universitario San Cecilio, Granada, 18016, Spain|Hospital Universitario Juan Ramón Jiménez, Huelva, 21005, Spain|Hospital Universitario de Jaén, Jaén, 23007, Spain|Hospital Regional Universitario de Málaga, Málaga, 29010, Spain|Hospital Virgen de la Victoria, Málaga, 29010, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain Less << | |
NCT01222455 | Hepatic Impairment|Healthy Vol... More >>unteers|Pharmacokinetics|Amount of R406 in Blood Less << | PHASE1 | COMPLETED | 2025-06-11 | Research Site, Orlando, Florid... More >>a, United States Less << |
NCT01640054 | Rheumatoid Arthritis | PHASE2 | TERMINATED | 2025-07-13 | Research Site, Hongkong, Shati... More >>n, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kitakyushu-shi, Fukuoka, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Kato-shi, Hyogo, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Nagasaki-shi, Nagasaki, Japan|Research Site, Omura-shi, Nagasaki, Japan|Research Site, Sasebo-shi, Nagasaki, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Tomigusuku-shi, Okinawa, Japan|Research Site, Hamamatsu-shi, Shizuoka, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Anyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Singapore, Thailand|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() | 1mg | 5mg | 10mg |
1 mM 5 mM 10 mM | 1.72mL 0.34mL 0.17mL | 8.61mL 1.72mL 0.86mL | 17.23mL 3.45mL 1.72mL |
Tags: Fostamatinib | R788 | R 788 | R-788 | Syk inhibitor | FLT3 inhibitor | Spleen tyrosine kinase | Cluster of differentiation antigen 135 | CD135 | Fms like tyrosine kinase 3 | Lyn inhibitor | Lck inhibitor | 901119-35-5
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL